Study: J&J and Bayer's anticoagulant Xarelto yields mixed results

04/5/2011 | Reuters

A clinical study found that Bayer and Johnson & Johnson's anticoagulant Xarelto worked as well as standard injectable drug Lovenox, by Sanofi-Aventis, in preventing blood clots after 10 days of treatment among patients hospitalized for acute illnesses. However, the incidence of bleeding among Xarelto users after 35 days of treatment was more than double the rate seen in Lovenox users.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
European Sales Manager
SentreHEART, Inc.
Germany, Benelux, UK
REG AFFAIRS PROJ MGR - 1400000A7F
Abbott
San Jose, CA
SPECIALIST II SYSTEMS INTEGRATION - 140000033P
Abbott
Dallas, TX
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD